FSCN1 and ovarian cancer: In different cancers, including colon, pancreatic, breast, lung, esophagus, stomach, skin, and ovarian cancers, elevated expression of FSCN1 is associated with increased metastatic potential and poor prognosis, indicating its role as a candidate potential biomarker and therapeutic target [19].